MX2014011573A - Use of serotonin reuptake inhibitor for treating central nervous system disorders. - Google Patents

Use of serotonin reuptake inhibitor for treating central nervous system disorders.

Info

Publication number
MX2014011573A
MX2014011573A MX2014011573A MX2014011573A MX2014011573A MX 2014011573 A MX2014011573 A MX 2014011573A MX 2014011573 A MX2014011573 A MX 2014011573A MX 2014011573 A MX2014011573 A MX 2014011573A MX 2014011573 A MX2014011573 A MX 2014011573A
Authority
MX
Mexico
Prior art keywords
nervous system
central nervous
serotonin reuptake
reuptake inhibitor
system disorders
Prior art date
Application number
MX2014011573A
Other languages
Spanish (es)
Other versions
MX366673B (en
Inventor
Martha Sonia Morales Ríos
Benjamín García Vázquez
Benjamín Florán Garduño
María Trinidad Serrano Alva
Original Assignee
Ct De Investigación Y De Estudios Avanzados Del I P N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Investigación Y De Estudios Avanzados Del I P N filed Critical Ct De Investigación Y De Estudios Avanzados Del I P N
Priority to MX2014011573A priority Critical patent/MX366673B/en
Publication of MX2014011573A publication Critical patent/MX2014011573A/en
Publication of MX366673B publication Critical patent/MX366673B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention refers to imidazoline indol such as 3-[2-(4,5-dihydro-1H-imidazol-2-yl)ethyl]-5-fluoro-1H-indol and the pharmaceutically acceptable salts thereof, which blocks the extracellular reuptake of the serotonin monoaminergic neurotrasnsmitter (5-hidroxytriptamine or 5-HT) in the presynaptic neuron, thus increasing the effective concentration of this neurotransmitter so as to be linked to the postsynaptic receptors 5-HT. The compounds of the invention are applied in neuro-psychiatric diseases such as depression.
MX2014011573A 2014-09-25 2014-09-25 Use of serotonin reuptake inhibitor for treating central nervous system disorders. MX366673B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2014011573A MX366673B (en) 2014-09-25 2014-09-25 Use of serotonin reuptake inhibitor for treating central nervous system disorders.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2014011573A MX366673B (en) 2014-09-25 2014-09-25 Use of serotonin reuptake inhibitor for treating central nervous system disorders.

Publications (2)

Publication Number Publication Date
MX2014011573A true MX2014011573A (en) 2015-03-10
MX366673B MX366673B (en) 2019-07-12

Family

ID=53189334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011573A MX366673B (en) 2014-09-25 2014-09-25 Use of serotonin reuptake inhibitor for treating central nervous system disorders.

Country Status (1)

Country Link
MX (1) MX366673B (en)

Also Published As

Publication number Publication date
MX366673B (en) 2019-07-12

Similar Documents

Publication Publication Date Title
EA201992474A2 (en) 5HT AGONISTS FOR TREATMENT OF DISORDERS
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2018000396A (en) Substituted aza compounds as irak-4 inhibitors.
MX2021014508A (en) Organic compounds.
CL2016002072A1 (en) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease
SV2017005434A (en) 2-AMINO-3,5-DIFLUORO-6-METHYL-6-PHENYL-3,4,5,6-TETRAHYDROPIRIDINS IN QUALITY OF BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NZ737399A (en) Ccr2 modulators
MX2017014192A (en) Compositions and methods of treating a neurodegenerative disease.
CL2015002529A1 (en) Tetrahydropyrrolothiazine Compounds
EA201171063A1 (en) PHARMACEUTICAL COMPOSITIONS OF OLMESARTAN
EA201791259A1 (en) DERIVATIVES OF PIPERIDINE AS HDAC1 / 2 INHIBITORS
CL2016002084A1 (en) Compounds derived from cyclopentane 1,2 substituted as orexin receptor antagonists.
CY1122264T1 (en) PPAR COMPOUNDS FOR USE IN THE TREATMENT OF FIBROTIC DISEASES
PH12016502347A1 (en) 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors
EA201691997A1 (en) 2,4-TIAZOLINIDON DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
PH12017500821A1 (en) Morpholine and 1, 4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
ECSP16078779A (en) CONDENSED HETEROCYCLES REPLACED AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA, AND RELATED DISORDERS
EA201791021A1 (en) 1- [2- (AMINOMETHYL) BENZYL] -2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO [3,2-d] PYRIMIDIN-4-ONE AS INHIBITORS MYELOPEROXIDASE
MX2017005484A (en) Dopamine d3 receptor antagonists compounds.
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
AR092103A1 (en) LAQUINIMOD IN THE TREATMENT OF DISORDERS MEDIATED BY THE CANABINOID RECEIVER OF TYPE 1 (CB1)
MX2018002446A (en) Fused heterocyclic compounds as s1p modulators.
MX2020003185A (en) Novel heterocyclic compounds as modulators of mglur7.

Legal Events

Date Code Title Description
FG Grant or registration